A Clinical Trial to Study the Effect of a Single Dose of MK-8527 on the Pharmacokinetics of Methadone

What this Trial Is About

This research aims to explore the effects of a study drug called MK-8527 when taken together with methadone in healthy adult volunteers. The study focuses on understanding how methadone behaves in the body over time after taking MK-8527, providing important information about the interaction between these two drugs. The trial is a Phase 1 clinical trial sponsored by Merck Sharp Dohme LLC and includes healthy participants aged 18 to 65 years with specific health criteria. Participants will receive both methadone and MK-8527 orally as part of the experimental treatment. The study measures how the body processes methadone over a 24-hour period after dosing, analyzing specific levels of methadone in the blood. The trial does not include a placebo group and involves careful monitoring of drug concentrations and participant safety during and after treatment. During the study, participants will undergo blood tests to measure methadone levels and observe any side effects or adverse events for up to six weeks. Researchers will track the maximum concentration of methadone, its presence in the blood at various times, and any reactions that might cause participants to stop treatment. The entire study duration and follow-up provide a detailed understanding of drug interactions and participant safety.

A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)